Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
3 INNOVATION
Sabatolimab: STIMULUS program progressing in MDS and AML
MDS
2019
AML
STIMULUS MDS-1
Phase 2 HMA combination,
enrollment complete
2020
CR Readout
PFS Readout (-2022-2023)
STIMULUS MDS-2
Phase 3 HMA combination
OS Readout (-2023)
2021
STIMULUS AML-1
Phase 2 HMA + venetoclax combination
Unfit AML
2022
2023
CR Readout (-2023)
Ph1 sabatolimab + HMA data showed
promising and durable response rates
(58% ORR in MDS1)
STIMULUS MDS-1: Ph2 randomized,
double-blind, 2 primary endpoints: CR, PFS
In June 2021, the DMC determined that the
study should continue blinded until PFS
readout (event-driven)
STIMULUS MDS-2: Ph3 randomized,
double-blind, primary endpoint: OS
(event-driven)
Enrollment ahead of target
■ Parallel execution of trials offers a range of filing options between 2022 and 2023 depending on PFS and/or OS outcomes
STIMULUS program has expanded with additional trials in AML and MDS including low-risk MDS
AML - Acute Myeloid Leukemia
1. Wei A et al., EHA, June 2021.
MDS Myelodysplastic Syndrome CR Complete Remission PFS Progression-free Survival ORR Overall response rate
OS Overall Survival DMC - Data Monitoring Committee
16 Investor Relations | Q2 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation